Royal Bank of Canada’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Royal Bank of Canada’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-6,038	Closed	-$1K	–	7343
2019 Q3	$1K	Buy	6,038 +338	+6%	+$229	﹤0.01%	6615
2019 Q2	$5K	Hold	5,700	–	–	﹤0.01%	6361
2019 Q1	$13K	Sell	5,700 -700	-11%	-$1.9K	﹤0.01%	5879
2018 Q4	$15K	Sell	6,400 -1,222	-16%	-$10.8K	﹤0.01%	5719
2018 Q3	$112K	Buy	7,622 +192	+3%	+$3.05K	﹤0.01%	4801
2018 Q2	$113K	Buy	7,430 +1,725	+30%	+$29.3K	﹤0.01%	4751
2018 Q1	$107K	Buy	5,705 +5,661	+12,866%	+$99K	﹤0.01%	4664
2017 Q4	$1K	Sell	44 -310	-88%	-$6.56K	﹤0.01%	6462
2017 Q3	$8K	Buy	+354	New	+$7.77K	﹤0.01%	6342

Other funds holding SNNA

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Private Ocean San Rafael, California $1.13B AUM 11.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Royal Bank of Canada's SNNA Position: Q4 2019 in Review

Royal Bank of Canada sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q4 2019, closing a stake of 6,038 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in SNNA in Q3 2017 and held it in 9 quarters. The position peaked at $113K in Q2 2018. 4 funds tracked by Wall St. Rank hold SNNA as of Q4 2019.

Royal Bank of Canada reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
Royal Bank of Canada sold 6,038 Sienna Biopharmaceuticals, Inc. shares in Q4 2019, an estimated $1K.
Royal Bank of Canada first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2017 and held it in 9 quarters.
Royal Bank of Canada's Sienna Biopharmaceuticals, Inc. position peaked at $113K in Q2 2018.
4 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q4 2019.

Based on Royal Bank of Canada's 13F filing for Q4 2019, filed 14 Feb 2020.